

## 英語論文 総説

1. Ozaki A, Tanimoto T, **Saji S**. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer (Correspondence). *N Engl J Med*, 373:1672-1673, 2015.
2. **Saji S**, **Kimura-Tsuchiya R**, **Sasaki E**. Molecular diagnostics for precision medicine in breast cancer treatment: what does the future hold? (Editorial). *Breast Cancer*. 2015 Nov 3. [Epub ahead of print]
3. Sato F, **Saji S**, Toi M. Genomic tumor evolution of breast cancer. *Breast Cancer*. 2015 May 22. [Epub ahead of print]
4. Toi M, Masuda N, Ishiguro H, **Saji S**, Ohno S, Chow LW. Development of breast cancer therapy: biomarker-driven and response-guided approaches in a neoadjuvant setting. *Int J Biol Markers*. 30(2):e252-3, 2015.
5. **Saji S**, **Kimura-Tsuchiya R**. Combination of molecular-targeted drugs with endocrine therapy for hormone-resistant breast cancer. *Int J Clin Oncol*. 20(2):268-72. 2015.
6. Niikura N, **Saji S**, Tokuda Y, Iwata H. Brain Metastases in Breast Cancer. *Jpn J Clin Oncol*. 44(12): 1133-1140, 2014.

## 英語論文 原著

1. Matsuyama T, Ishikawa T, Okayama T, Oka T, Adachi S, Mizushima K, **Kimura R**, Okajima M, Sakai H, Sakamoto N, Katada K, Kamada K, Uchiyama K, Handa O, Takagi T, Kokura S, Naito Y, Itoh Y. Tumor inoculation site affects the development of cancer cachexia and muscle wasting. *Int J Cancer*. 2015 Dec;137(11):2558-65
2. Honma N, Horii R, Ito Y, **Saji S**, Younes M, Iwase T, Akiyama F. Differences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy. *BMC Cancer*. 2015 Oct 15;15(1):698.
3. Hojo T, Masuda N, Mizutani T, Shibata T, Kinoshita T, Tamura K, Hara F, Fujisawa T, Inoue K, **Saji S**, Nakamura K, Fukuda H, Iwata H. Intensive vs. Standard Post-Operative Surveillance in High-Risk Breast Cancer Patients (INSPIRE): Japan Clinical Oncology Group Study JCOG1204. *Jpn J Clin Oncol*. 45(10):983-6 2015.
4. Hayashi N, Niikura N, Masuda N, Takashima S, Nakamura R, Watanabe K, Kanbayashi C, Ishida M, Hozumi Y, Tsuneizumi M, Kondo N, Naito Y, Honda Y, Matsui A, Fujisawa T, Oshitanai R, Yasojima H, Yamauchi H, **Saji S**, Iwata H. Prognostic factors of HER2-positive breast cancer patients who develop brain metastasis: a multicenter retrospective analysis. *Breast Cancer Res Treat*. 49(1):277-84. 2015.
5. Yagata H, Ohtsu H, Komoike Y, **Saji S**, Takei H, Nakamura T, Ohashi Y, Iwase T, Shimozuma K. Joint symptoms and health-related quality of life in postmenopausal women with breast cancer who completed 5 years of anastrozole. *Support Care Cancer*. 2015 Jul 8. [Epub ahead of print]
6. Kurebayashi J, Miyoshi Y, Ishikawa T, **Saji S**, Sugie T, Suzuki T, Takahashi S, Nozaki M, Yamashita H, Tokuda Y, Nakamura S. Clinicopathological characteristics of breast cancer and trends in the management of breast cancer patients in Japan: Based on the Breast Cancer Registry of the Japanese Breast Cancer Society between 2004 and 2011. *Breast Cancer*. 22(3):235-44. 2015.
7. Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Heeson S, Clark E, Ross G, Benyunes MC, Cortés J; **CLEOPATRA Study Group**. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. *N Engl J Med*. 2015. 372(8):724-34
8. Honma N, Horii R, Iwase T, **Saji S**, Younes M, Ito Y, Akiyama F, Ki-67 evaluation at the hottest spot predicts clinical outcome of patients with hormone receptor-positive/HER2-negative breast cancer treated with adjuvant tamoxifen monotherapy, *Breast Cancer*, 22(1):71-8, 2015.

9. Fujita Y, Kishimoto M, Nakao R, **Kimura-Tsuchiya R**, Yagi N, Yanagisawa A. Incidence of lymphatic involvement in differentiated-type intramucosal gastric cancers as examined by endoscopic resection. *Gastric Cancer*. 2015 Feb 1. [Epub ahead of print]
10. Takemoto K, Hatano E, Iwaisako K, Takeiri M, Noma N, Ohmae S, Toriguchi K, Tanabe K, Tanaka H, Seo S, Taura K, Machida K, Takeda N, **Saji S**, Uemoto S, Asagiri M. Necrostatin-1 protects against reactive oxygen species (ROS)-induced hepatotoxicity in acetaminophen-induced acute liver failure. *FEBS Open Bio*. Sep 6;4:777-87. 2014.
11. Niikura N, Hayashi N, Masuda N, Takashima S, Nakamura R, Watanabe KI, Kanbayashi C, Ishida M, Hozumi Y, Tsuneizumi M, Kondo N, Naito Y, Honda Y, Matsui A, Fujisawa T, Oshitanai R, Yasojima H, Tokuda Y, **Saji S**, Iwata H. Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis. *Breast Cancer Res Treat*. 147(1):103-12, 2014.
12. Honma N, Horii R, Iwase T, **Saji S**, Younes M, Ito Y, Akiyama F. Proportion of estrogen or progesterone receptor expressing cells in breast cancers and response to endocrine therapy. *Breast*. 23(6):754-62, 2014.
13. Ueno T, Masuda N, Yamanaka T, **Saji S**, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Sasano H, Toi M. Evaluating the 21-gene assay Recurrence Score as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer, *Int J Clin Oncol*, 2014 Aug;19(4):607-13.
14. **Kimura-Tsuchiya Reiko**, Ishikawa T, Kokura S, Mizushima K, Adachi S, Okajima M, Matsuyama T, Okayama T, Sakamoto N, Katada K, Kamada K, Uchiyama K, Handa O, Takagi T, Yagi N, Naito Y, Itoh Y. The inhibitory effect of heat treatment against epithelial-mesenchymal transition (EMT) in human pancreatic adenocarcinoma cell lines. *J Clin Biochem Nutr*. 2014 Jul;55(1):56-61.

## 日本語論文 総説

1. 鈴木礼子、**佐治重衡**  
やせ・肥満と乳がん発生リスク—女性のライフステージ別に異なる可能性について—  
癌と化学療法、42(5):525-528, 2015.
2. 大津敦、赤司浩一、**佐治重衡**、吉村清  
座談会 抗体治療の新展開  
がん分子標的治療、13(2):224-231, 2015.
3. **佐治重衡**  
総説論文というもの (エッセイ)  
日本癌病態治療研究会誌、21(1):47-48, 2015.
4. 山口絢音、**佐治重衡**、戸井雅和  
閉経前ホルモン受容体陽性早期乳がんに対する術後内分泌療法  
腫瘍内科、15(5):438-443, 2015.
5. 津田萌、石黒洋、**佐治重衡**  
内分泌療法薬の作用機序と副作用：概論  
日本臨床 73(suppl 2), 291-297, 2015.
6. 今村知世、**佐治重衡**  
ホルモン受容体陽性乳がんに対するタモキシフェン治療と CYP2D6 遺伝子多型  
がん分子標的治療、12(4): 449-455, 2014.
7. 佐藤史顕、**佐治重衡**、戸井雅和  
State of the Art: Genetic tumor evolution  
Cancer Board 乳癌、7(2), 23-30, 2014.

8. 林直輝、山内英子、**佐治重衡**  
乳癌患者におけるアロマターゼ阻害薬と骨粗鬆症  
The BONE, 28(4), 69-74, 2014.
9. **佐治重衡**、**木村礼子**  
閉経前、腋窩リンパ節転移陽性、Luminal A 乳癌の治療 b) 術前薬物療法  
外科, 76(13): 1550-1553, 2014.
10. 清水華子、諏訪裕文、**佐治重衡**  
抗 HER2 療法の新時代 ALTO 試験の結果から  
腫瘍内科, 14(3):268-272, 2014.
11. 河口浩介、鈴木栄治、**佐治重衡**  
乳がんの抗 HER2 療法耐性機序とその克服  
がん分子標的治療 Vol. 12No. 2: 13-19, 2014
12. 土肥 統、八木信明、**木村礼子**、鎌田和浩、内藤裕二、伊藤義人  
残胃の早期胃癌に対する ESD の実際  
消化器の臨床, 17(3):264-268, 2014

## 書籍

1. **佐々木栄作**  
CQ23 DS 療法(DTX+S-1)をどう使いこなすか?  
CQ24 weekly PTX 療法をどう使いこなすか?  
胃がん薬物療法 Q&A、佐藤温編、ヴァンメディカル、72-75、2015.
1. **佐々木栄作**  
第 1 章抗がん剤の副作用と治療 8. 神経障害 116-121  
第 4 章レジメン別の副作用 2. 頭頸部がん 346-348  
改訂版 がん化学療法副作用対策ハンドブック、岡元るみ子・佐々木常雄編、羊土社、  
2015.
2. **佐治重衡**  
乳癌の分子生物学と mTOR  
エベロリムスによる乳癌治療の新展開、野口眞三郎編、メディカルレビュー社、30-37、  
2014.